In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European Journal of Human Genetics

• Publication date

  2012-11-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/ejhg.2012.261PMID 23188051PMCID PMC3722955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Faculty Opinions recommendation of Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.

  2014cited by this paper
• Peripheral Administration of Antisense Oligonucleotides Targeting the Amyloid-β Protein Precursor Reverses AβPP and LRP-1 Overexpression in the Aged SAMP8 Mouse Brain

  2012cited by this paper
• Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

  2012cited by this paper
• Genetic testing and screening of individuals at risk of NF2

  2012cited by this paper
• Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy

  2011cited by this paper
• Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model

  2011cited by this paper
• Effects of splicing mutations on NF2‐transcripts: Transcript analysis and information theoretic predictions

  2011cited by this paper
• Targeting RNA to treat neuromuscular disease

  2011cited by this paper
• Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics

  2010cited by this paper
• New insights in gene‐derived therapy: the example of Duchenne muscular dystrophy

  2010cited by this paper
• Neurofibromatosis type 2.

  2009cited by this paper
• Further genotype – phenotype correlations in neurofibromatosis 2

  2009cited by this paper
• Gene Knockdowns in Adult Animals: PPMOs and Vivo-Morpholinos

  2009cited by this paper
• Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations

  2009cited by this paper
• Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac.

  2007cited by this paper
• Mutational spectrum of the NF2 gene: a meta‐analysis of 12 years of research and diagnostic laboratory findings

  2007cited by this paper
• Neurofibromatosis type 2

  2007cited by this paper
• The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene

  2006cited by this paper
• Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin.

  2005cited by this paper
• Management of the patient and family with neurofibromatosis 2: a consensus conference statement

  2005cited by this paper
• Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas

  2003cited by this paper
• NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions.

  2003cited by this paper
• The Neurofibromatosis Type 2 Gene Product, merlin, Reverses the F-Actin Cytoskeletal Defects in Primary Human Schwannoma Cells

  2002cited by this paper
• Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects

  2000cited by this paper
• Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients.

  2000cited by this paper
• Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides*

  1999cited by this paper
• A G-->A transition creates a branch point sequence and activation of a cryptic exon, resulting in the hereditary disorder neurofibromatosis 2.

  1998cited by this paper
• Phenotypic variability associated with 14 splice-site mutations in the NF2 gene.

  1998cited by this paper
• Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis.

  1998cited by this paper
• Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells

  1998cited by this paper
• Morpholino Antisense Oligomers: Design, Preparation, and Properties

  1997cited by this paper
• Screening for germ‐line mutations in the NF2 Gene

  1995cited by this paper
• Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.

  1993cited by this paper
• A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

  1993cited by this paper

• Gene therapy and genome-editing for schwannoma in NF2-related schwannomatosis: current understanding and future directions

  2025cites this paper
• The evolving landscape of NF gene therapy: Hurdles and opportunities

  2025cites this paper
• Molecular pathogenesis of the schwannomatosis genes and genetic testing strategies

  2025cites this paper
• Genomics of vestibular schwannoma.

  2025cites this paper
• Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype in vitro

  2022cites this paper
• Antisense oligonucleotides targeting exon 11 are able to partially rescue the Neurofibromatosis Type 2 phenotype in vitro

  2022cites this paper
• Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology

  2022cites this paper
• Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing

  2022cites this paper
• Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation

  2021cites this paper
• Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes

  2021influential citation
• Revisiting the UK Genetic Severity Score for NF2: a proposal for the addition of a functional genetic component

  2021cites this paper
• Targeted massively parallel sequencing of candidate regions on chromosome 22q predisposing to multiple schwannomas: An analysis of 51 individuals in a single‐center experience

  2021cites this paper
• Variant effect on splicing regulatory elements, branchpoint usage, and pseudoexonization: Strategies to enhance bioinformatic prediction using hereditary cancer genes as exemplars

  2020cites this paper
• Therapeutic Approaches for NF1

  2020cites this paper
• Revisiting the UK Genetic Severity Score for NF2: a proposal for adding functional information

  2020cites this paper
• Transposon clusters as substrates for aberrant splice-site activation

  2020cites this paper
• Understanding human DNA variants affecting pre-mRNA splicing in the NGS era.

  2019cites this paper
• Deep intronic mutations and human disease

  2017cites this paper
• Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene

  2016cites this paper
• Preand posttranscriptional genetic information modification in muscular dystrophy treatment

  2016cites this paper
• Thérapie génique par saut d'exon : application à une Myopathie à Core et à un cas de syndrome OculoCérébroRénale de Lowe

  2014cites this paper
• Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases

  2014cites this paper
• Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma

  2014cites this paper
• Making Use of Aberrant and Nonsense: Aberrant Splicing and Nonsense-Mediated Decay as Targets for Personalized Medicine

  2013cites this paper
• Can manipulation of splicing offer gene therapy possibilities to those with tumour-prone disorders?

  2012cites this paper